Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NEW PRODUCTS
December 20, 2004
- Dainippon to Beef Up Sales of Prorenal
December 20, 2004
- New Company to Focus on OB/GYN, ENT, CV Areas: Teikoku Hormone, Grelan
December 20, 2004
- BUSINESS NEWS IN BRIEF -2-
December 20, 2004
- WEBSITE NEWS
December 20, 2004
- NEW PRODUCTS
December 20, 2004
- Eliminate Provisional Delivery, Clarify Allowance Payment Criteria: Ryukaikon
December 20, 2004
- Committee Calls For Patents on Combinations of Drugs, New Administration Methods
December 20, 2004
- REGULATORY NEWS IN BRIEF
December 20, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 20, 2004
- AstraZeneca to Boost Its Market Share to 4.3-4.5% by 2010: New President Kato
December 20, 2004
- PRESS SEMINAR
December 20, 2004
- MONITOR
December 20, 2004
- Most Widely Used Generics Are from Research-oriented Companies: JSGM Survey
December 20, 2004
- Dainippon, Sumitomo "Need to Consider Further M&A": Datamonitor
December 20, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 20, 2004
- ABeam Consulting Lists 5 Factors for Successful M&As
December 20, 2004
- Sanjiu Honsoudou Medical & Pharm. to Create Drug Wholesaler in China
December 20, 2004
- Eisai to Strengthen Business Infrastructure in China, India
December 20, 2004
- MEDICAL DEVICE NEWS IN BRIEF
December 20, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…